BrainsWay Announces Positive Results in Late-Life Depression Post-Marketing Analysis

Data Published in Leading Peer-Reviewed Publication, Journal of Clinical Medicine

JERUSALEM and BURLINGTON, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, announced positive results in a recently published post-marketing study of its Deep Transcranial Magnetic Stimulation (Deep TMS) for the treatment of late-life depression.

The data were highlighted in an article entitled, “Never Too Late: Safety and Efficacy of Deep TMS for Late-Life Depression,” that was published in the Journal of Clinical Medicine, an international, peer-reviewed, open access journal. The post-marketing study demonstrated real-world outcomes for older adults (60-91 years of age) suffering from major depressive disorder (MDD). In the study, data was analyzed from 247 depression patients at 16 clinical sites in this age group who had been treated with BrainsWay’s proprietary H1 Coil. The results showed a 79.4% response rate (≥50% reduction in symptoms) and a 60.3% remission rate for those patients who had received at least 30 treatment sessions, and were based on the rating scale that was most utilized for each individual patient. The outcomes were comparable to those reported in a post-marketing analysis of over 1,350 patients published in 2023.

"As our population is living longer, late-life depression is fast becoming a critical health care concern that affects a significant number of families and care facilities worldwide. While the use of noninvasive neurostimulation with TMS has shown excellent efficacy for depression patients aged 20-65, there has been some concern that older adults may not receive adequate relief due to typical age-related changes in their brains. Specifically, as we get older, the distance from our scalp to our brain tends to expand due to brain atrophy. This can make it challenging for certain non-invasive technologies to reach the brain areas involved in depression,” said Colleen Hanlon, PhD, Vice President of Medical and Clinical Affairs at BrainsWay. “We believe that the deeper and broader stimulation of BrainsWay’s Deep TMS can play a meaningful role in overcoming these age-related challenges.”